Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers
Clinical Cancer Research, 04/03/08

Aaltonen K et al. – Cyclin E and cyclin D1 expression distinguishes non-BRCA1/2 tumors from both sporadic and BRCA1- and BRCA2-associated tumors and may reflect different predisposition and pathogenesis in these groups

Methods

Immunohistochemical anaylsis of cyclin E and D1 in tissue microarrays of 53 BRCA1, 58 BRCA2, 798 familial non-BRCA1/2, and 439 sporadic breast tumors

Results

BRCA1 tumors had significantly more frequently high cyclin E (88%) and low cyclin D1 (84%) expression than sporadic (54%; 49%) or familial non-BRCA1/2 (38%; 45%) tumors
BRCA2 tumors had significantly more frequently low cyclin D1 expression (68%) than sporadic or familial non-BRCA1/2 tumors and significantly more frequently high cyclin E expression than familial non-BRCA1/2 tumors
Cyclin expression, early age of onset, and estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) status were independent factors most clearly distinguishing tumors of BRCA1 mutation carriers from other familial breast cancers
High cyclin E and low cyclin D1 expression were independent predictors of BRCA2 mutation compared with familial non-BRCA1/2 tumors
Lower frequency of high cyclin E expression independently distinguished familial non-BRCA1/2 tumors from sporadic tumors

<< Previous
Gene expression signatures, clinicopathological features, and...

Next >>
Prospective phase II trial of a combination of fixed dose rate...